Literature DB >> 9174448

Dynamics of hip joint remodeling after Chiari osteotomy. 10 patients with neuromuscular disease followed for 8 years.

W R Osebold1, E L Lester, P Watson.   

Abstract

We analyzed the development of 10 hips in 10 consecutive patients with neuromuscular disease (9 with spasticity, 1 with Charcot-Marie-Tooth disease) who had undergone Chiari osteotomy for painful hip subluxation or dislocation. The patients were 11 (5-19) years old at surgery and follow-up time was 8 (6-11) years. The Chiari osteotomy particularly improved and maintained femoral head coverage. These parameters did not show the postoperative deterioration noted in some other studies. The osteotomy did not improve femoral head lateral displacement. Throughout the postoperative period, the configuration of the proximal femur and the height of the joint cartilage were unchanged and undisturbed, indicating that osteotomy did not place excessive or uneven pressure on the femoral head. The ambulatory status of the patients was dependent on the severity of the underlying disease, and was not improved by osteotomy. However, pain associated with subluxation or dislocation was reduced in 9 of the patients.

Entities:  

Mesh:

Year:  1997        PMID: 9174448     DOI: 10.3109/17453679709003994

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  3 in total

1.  Hip stress reduction after Chiari osteotomy.

Authors:  S Herman; A Jaklic; S Herman; A Iglic; V Kralj-Iglic
Journal:  Med Biol Eng Comput       Date:  2002-07       Impact factor: 2.602

2.  Observations on the development of the acetabulum following Chiari osteotomy.

Authors:  W R Osebold; E L Lester; Patrice Watson
Journal:  Iowa Orthop J       Date:  2002

3.  Treatment outcome of dome osteotomy of the pelvis combined with trochanteric advancement for sequelae of Perthes' disease.

Authors:  Asep Santoso; Pramod Shaligram Ingale; Ik-Sun Choi; Young-Rok Shin; Kyung-Soon Park; Taek-Rim Yoon
Journal:  Acta Orthop Traumatol Turc       Date:  2018-03-26       Impact factor: 1.511

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.